Eli Lilly launches Employer Connect platform to boost U.S. obesity care access via Zepbound at $449 for all doses. Partners with 15+ admins for employer benefits, tackling $1.7T economic burden.
Written By: Sana Khan BPharm
Reviewed By: Pharmacally Editorial Team
Eli Lilly and Company has unveiled its Employer Connect platform; a new initiative aimed at expanding access to obesity management medications for U.S. employees. By partnering with over 15 independent program administrators, the platform empowers employers to create flexible, transparent benefits solutions that reduce out-of-pocket costs and address inconsistent coverage in employer-sponsored plans.
Obesity impacts more than 100 million American adults, driving annual U.S. economic costs exceeding $1.7 trillion including $480 billion in direct medical expenses and $1.24 trillion in lost productivity.
Despite its status as a chronic disease, roughly half of commercially insured employees lack coverage for obesity treatments. “For far too many people living with obesity, starting or staying on treatment isn’t just a medical decision it’s an access decision driven by coverage and cost,” said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities.
Scaling Access with Tailored Solutions
The platform launches with nationwide pharmacy support from partners like HealthDyne and CenterWell, offering options from basic benefits administration to comprehensive care including clinical support and behavior-change programs.
Employers gain control to customize programs that fit their workforce and budget, preserving patient and provider choice.
“By enabling coverage outside traditional benefit designs, we lower barriers to treatment,” noted Kevin Hern, senior vice president of Lilly Employer.
Key administrators include 9amHealth, Calibrate Health, GoodRx, Mark Cuban Cost Plus Drug Company, Teladoc Health, and others.
Affordable Pricing and Zepbound Availability
At the core is Lilly’s Zepbound® (tirzepatide) KwikPen®, available to network pharmacies at a discounted $449 for all doses, final employer and employee costs vary by chosen model and fees. This pricing enhances cost predictability while pairing medication with services like virtual care.
Zepbound, the most prescribed weight management medication in 2025 per FDA data, is approved for adults with obesity or overweight plus weight-related conditions, and for moderate-to-severe obstructive sleep apnea (OSA) in obesity.
The single-patient-use KwikPen delivers four weekly doses. Doses range from 2.5 mg (starting) to 15 mg maintenance, injected subcutaneously weekly.
Clinical highlights include:
- SURMOUNT-1 trial: 20.9% average body weight loss at 15 mg over 72 weeks vs. 3.1% placebo.
- SURMOUNT-5: 50 lbs (20.2%) average loss vs. 33 lbs (13.7%) on Wegovy.
Zepbound contains tirzepatide and carries important safety warnings, including the potential risk of thyroid C-cell tumors. Do not use Zepbound if you or any family member has a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Patients should also avoid it if they have experienced a serious allergic reaction to tirzepatide or any of its ingredients, or if using other tirzepatide-containing products or GLP-1 receptor agonist medicines.
Lilly plans to expand administrator options, positioning Employer Connect as a pivotal step in making evidence-based obesity care more equitable.
Reference
Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients, 05 March 2026, Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients | Eli Lilly and Company
About Writer
Sana Jamil Khan, B.Pharm
She is a pharmacy graduate with a keen interest in clinical research, pharmacovigilance, and medical writing, with a growing focus on publication and scientific content development. In her words, she is passionate about translating complex medical data into clear, evidence-based communication.